Bio.be - Belgium showcases expertise on Immunotherapy at the world’s largest Biotechnology Conference
Bio US San Diego hosts a Belgian workshop
• R&D Investments continue to grow: 3.4 billion € in 2016 (+123% compared to 2006)
Showcasing our expertise in Immunotherapy: the new paradigm shift in cancer treatment
The BIO International Convention 2017 is the largest global biotechnology conference and exhibition, hosting more than 18.000 experts. On June 19, Belgium organizes a workshop on ‘Immunotherapy: a cure for cancer?’ Belgian key players including Celyad and PDC*Line Pharma showcase recent breakthroughs, and argenx (ARGX) and iTeos Therapeutics demonstrate how they charmed respectively AbbVie and Pfizer into major collaborations.
Belgium’s expertise in this area was already clear through the recent white paper showcasing Belgium’s expertise in immunotherapy, which got a lot of attention in the worldwide life sciences community.
Showcasing an internationally reputable ecosystem
Belgian life sciences companies successfully partnered with large pharmaceutical companies, resulting in a cumulative value of licensing and R&D contracts signed over the last 12 years of more than 18 billion €. More than 4 billion € has already been received as milestone payments. More than 70% of the 21,5 billion € market cap of Belgian listed companies (15 billion €) is coming from investors outside Belgium.
Belgium again attends the BIO International Convention 2017 with a stunning number of 135 delegates representing 74 companies and organizations. The Belgian delegation comes together in one of the most vibrant pavilions of the conference. Worldwide companies and partners do not only visit the Belgian pavilion to receive an invitation for one of the most popular social events at BIO: the Belgian Café; they want to meet the Belgian companies for their expertise, their technology and their creativity and to find out more about the thriving environment Belgium offers as a life sciences ecosystem.
Informatie - Information
Niels De Smet - Turnstone Communications